Allergan Looks To Sell Women’s Health, Infectious Disease Businesses

Allergan Looks To Sell Women’s Health, Infectious Disease Businesses

Research  these Stocks on Kapitall’s Playground Now

 
research now

by: Elizabeth Balboa, Benzinga Staff Writer

 

Allergan plc AGN 0.78% has concluded its strategic review and now plans to sell its women’s health and infectious disease businesses, according to CNBC.

 

What Happened 

Allergan will redirect its focus to medical aesthetics and dermatology, ophthalmology, central nervous system and gastroenterology.

Shares initially fell 3 percent on the news but largely recovered by the time of publication Wednesday. 

 

Why It’s Important

Cowen recently valued Allergan’s women’s health segment at around $4 billion and infectious diseases at $2 billion. Their sale would leave behind a growing set of assets Barclays considers central to the bull thesis.

 

What’s Next

CNBC’s David Faber suggested prospective buyers may opt to wait on the women’s health business until an August target date for a candidate that's under regulatory review.

Faber additionally predicted the sale proceeds would support buybacks and debt reduction.

 

© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

stockstarsbanners640x1362jpg

2 responses to “Allergan Looks To Sell Women’s Health, Infectious Disease Businesses”

  1. soraj varshney says:

    thanks for sharing view design mode
    Literacy
    scale

Leave a Reply

Your email address will not be published. Required fields are marked *

wirebanner1jpg
  • See Most Recent Articles